Indivior 2Q operating profit $160M vs. $72M y/y

Indivior Pharmaceuticals, Inc. reported a second-quarter operating profit of $160 million for 2026, compared to $72 million in the same period of the previous year, reflecting significant operational improvements and strategic execution. The increase in operating profit was driven by strong performance in its flagship product, SUBLOCADE, which saw robust revenue growth and improved cost management.

For the second quarter of 2026, total net revenue reached $358 million, up 20% year-over-year from $298 million in the second quarter of 2025. SUBLOCADE, the company’s long-acting injectable treatment for opioid use disorder, contributed $252 million in net revenue, a 30% increase compared to $194 million in the prior-year quarter. This growth was supported by a 12% increase in dispense unit volume and favorable gross-to-net adjustments.

GAAP operating expenses for the quarter were $211 million, a 3% increase from $205 million in the second quarter of 2025. However, non-GAAP operating expenses, which exclude stock-based compensation and other non-recurring items, declined by 8% to $164 million from $179 million in the prior-year period. This reduction reflects the company’s focus on streamlining operations and reducing organizational complexity as part of its ongoing action agenda.

Indivior’s operating profit growth was also supported by a 91% increase in adjusted EBITDA, which reached $142 million for the quarter compared to $75 million in the second quarter of 2025. The company attributed this improvement to higher revenue, disciplined cost control, and the benefits of its strategic initiatives.

Looking ahead, Indivior reaffirmed its full-year 2026 financial guidance, which includes total net revenue in the range of $1,125 million to $1,195 million and adjusted EBITDA between $535 million and $575 million. The company also announced a new $400 million share repurchase program, underscoring its commitment to returning value to shareholders while maintaining a strong balance sheet.

These results highlight Indivior’s progress in executing its strategic priorities, including accelerating SUBLOCADE growth and improving operational efficiency. As the company moves forward, it remains focused on leveraging its market position and financial strength to drive long-term value creation.